Vericel - VCEL STOCK NEWS

Vericel Corporation (NASDAQ: VCEL) reported third quarter 2021 net revenue of $34.5 million, a 7% increase from $32.3 million in Q3 2020. Year-to-date revenue rose 38% to $108.6 million. Notably, MACI revenue was $23.9 million, and Epicel revenue was $9.8 million. The company faced a net loss of $4.9 million or $0.11 per share, contrasting with net income of $3.6 million in Q3 2020. Gross margin decreased to 64%, down from 70% the previous year. The company adjusted its full-year revenue guidance to reflect a projected increase of 27%-30%.

Vericel Corporation (NASDAQ:VCEL) has announced a webcast and conference call to discuss its third-quarter 2021 financial results and business highlights. The call is scheduled for November 9, 2021, at 8:30 AM EDT. Investors can access the call live via the company's Investor Relations website. Vericel operates in advanced therapies for sports medicine and severe burn care, marketing two cell therapy products: MACI® and Epicel®. The company also holds the exclusive North American commercial rights for NexoBrid®, aimed at severe burn treatment.

Vericel Corporation (NASDAQ:VCEL) announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference. The event is scheduled for Monday, September 13, 2021, at 4:15 p.m. Eastern Time. Investors can access the webcast through the Investor Relations section of Vericel's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®. For further details, visit www.vcel.com.

Vericel Corporation (NASDAQ:VCEL) has appointed Patrick J. Fowler as Senior Vice President of Corporate Development and Strategy, effective immediately. With over 15 years of experience in business development within the biotech sector, Fowler previously led strategy and operations at Sanofi, enhancing corporate growth and development strategies. The company anticipates Fowler's expertise will drive growth and enhance its innovative product portfolio, which includes MACI® and Epicel® for sports medicine and burn care.

Vericel Corporation (NASDAQ:VCEL) reported a **97%** increase in **total net revenue** for Q2 2021, reaching **$39.5 million**. Key products contributed with **MACI®** revenue at **$26.5 million** and **Epicel®** at **$12.2 million**. The company improved its gross margin to **68%** from **57%** year-over-year. Although net loss decreased to **$3.8 million** from **$8.3 million**, operating expenses rose to **$30.6 million**. Cash reserves increased to **$116 million**. Full-year revenue guidance was raised to **$168-$171 million**, indicating strong business momentum.

Vericel Corporation (NASDAQ:VCEL) will host a webcast and conference call on August 4, 2021, at 8:30 AM EDT to discuss its second-quarter 2021 financial results. Investors can join the call via telephone or through the company’s website. The presentation slides will also be available online. Vericel is known for its advanced therapies in sports medicine and severe burn care, marketing products like MACI® and Epicel®. The call will be accessible for replay until August 11, 2021. For further details, visit the Vericel investor relations page.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, announced that CEO Nick Colangelo will present at the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 9:00 a.m. Eastern Time. A live webcast of the presentation will be available on the company’s Investor Relations website. Vericel markets two key cell therapy products: MACI®, for knee cartilage repair, and Epicel®, a permanent skin replacement for severe burns. The company also has exclusive rights to NexoBrid®, a biological product for burn debridement.

Vericel Corporation (NASDAQ:VCEL) announced that its partner, MediWound Ltd., received a complete response letter (CRL) from the FDA regarding the Biologics License Application for NexoBrid, a treatment for severe burns. The FDA cited issues in the Chemistry, Manufacturing, and Controls (CMC) section, requiring additional information and inspections, which were hindered by COVID-19 travel restrictions. The FDA also highlighted concerns from good clinical practice inspections affecting the study's efficacy. Vericel remains committed to addressing these issues to expedite NexoBrid's approval.

Vericel Corporation (NASDAQ:VCEL) announced that CEO Nick Colangelo will present a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. Eastern Time. The event will be conducted virtually, allowing investors to access a live webcast via the Investor Relations section of Vericel's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, offering MACI and Epicel as leading cell therapy products.